Get to know our clinical trials
Clinical trial to evaluate different doses of RO7247669 in participants with previously untreated unresectable or metastatic melanoma.
THE MAIN OBJECTIVE IS TO EVALUATE THE CLINICAL ACTIVITY OF RO7247669 AT DOSES OF 600 MG AND 1200 MG ADMINISTERED EVERY 3 WEEKS.
Status
In recruitment
headquarters
Madrid
Technical Summary
- MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE II STUDY TO EVALUATE DIFFERENT DOSES OF RO7247669 IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA
- Code EudraCT: .
- Protocol number: BP43963
- Promoter: Roche Farma, S.A.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.